Home Blood Test Could Help Catch Alzheimer’s Risk Early, Study Finds

Only 1 in 1,000 People With Early Cognitive Decline See a Specialist. A Home Blood Test Could Change That.

A small pinprick on the fingertip. A dried blood spot card dropped in the mailbox. Results that could help flag whether someone needs a fuller medical evaluation for Alzheimer’s disease, all without a waiting room, a specialist appointment, or a vial of blood drawn from your arm. That future may be closer than most people think.

A new study published in Nature Communications found that two proteins linked to Alzheimer’s disease, detected through a self-administered finger-prick blood test completed at home, correlated meaningfully with memory and cognitive performance in older adults, and in some cases with measures of daily functioning. To be clear, this test would not diagnose Alzheimer’s disease. Researchers explored it as a way to flag people who may need a fuller medical evaluation, including those who might otherwise never reach a specialist clinic at all.

According to the paper, only about one in every 1,000 people with early cognitive decline currently receives a specialist evaluation. A reliable, easy-to-use home test could change that equation, not just in the UK, where the study was conducted, but globally, especially in rural areas where specialized medical care is hard to come by.

Two Proteins, One Small Card

Researchers focused on two proteins in the blood associated with Alzheimer’s disease. One, called p-tau217, is considered among the strongest blood-based signals for Alzheimer’s-related brain changes. Another, called GFAP, is a marker of brain cell stress and inflammation. Both have been studied using traditional blood draws, but this research examined whether they could be reliably detected from tiny amounts of blood collected at home through a finger prick, similar to the one used for at-home blood sugar checks, but with the blood applied to a dried blood spot card and mailed to a lab for analysis.

174 Older Adults Tested an Alzheimer’s Biomarker Kit at Home

Researchers recruited 226 participants through the PROTECT research program in the UK. Of those, 174 completed the blood test kits and were included in the final analysis. The average age was about 66, and just over half were female. The cohort included cognitively healthy participants, people with mild cognitive impairment, and 28 people diagnosed with dementia.

Participants completed a computerized cognitive test covering memory, attention, and mental skills needed for planning and problem-solving, and filled out standardized scales measuring their ability to handle daily activities like managing finances or medications.

A smaller subgroup of 40 participants also gave a traditional blood draw at a clinic, allowing researchers to directly compare the two collection methods.

Home Finger-Prick Results Matched Clinical Blood Draws

Both proteins detected through the finger-prick method correlated with performance on cognitive and functional tests. P-tau217 showed the strongest associations, particularly with memory scores and daily functioning. GFAP also correlated with planning ability and daily living skills. When researchers compared home finger-prick results against the traditional clinical blood draw in the 40-person subgroup, the correlation was strong, both in people with dementia and those without.

Researchers also developed a two-cutoff risk-sorting approach, combining p-tau217 levels with memory test scores to divide participants into high-risk, low-risk, and intermediate groups. People in the high-risk group performed worse on attention, executive function, and daily-function measures. People in the low-risk group performed better across the board. About 80% of participants completed the test without any assistance, guided only by written and video instructions. Nearly 78% said they would be willing to use it regularly as part of their routine healthcare.

A Surprise Finding About Heart Health

One of the more unexpected results involved GFAP. Even though both proteins identified people with cognitive problems, there was little overlap between individuals who tested high on GFAP and those who tested high on p-tau217. Only about 6% of participants were elevated on both.

Further analysis found that people with elevated GFAP were nearly five times more likely to report a history of heart disease compared to those with normal GFAP levels. P-tau217 showed no such connection. GFAP may be picking up a different pattern of risk, possibly related to vascular health, though that part of the study relied on self-reported heart-disease history and needs confirmation. For clinicians trying to understand why a patient’s thinking is declining, having both markers could paint a more complete picture.

Beyond everyday healthcare, this technology could also reshape how clinical trials for new Alzheimer’s treatments recruit participants. Screen failure rates in such trials, meaning people who enroll but don’t qualify after more detailed testing, can reach 90%. A simple at-home pre-screening tool could help researchers identify eligible participants far more efficiently.

For the many people with early cognitive changes who never make it through the door of a specialist clinic, a reliable, affordable, mailbox-ready blood test could be the first real shot at catching potential problems early. And for Alzheimer’s research and care, earlier evaluation is increasingly the goal.

---

Disclaimer: This article is based on a peer-reviewed research study, but findings have not been independently replicated and should not be taken as medical advice. The test described is not currently available for clinical or consumer use and has not been approved as a diagnostic tool. Anyone with concerns about memory or cognitive health should consult a qualified medical professional.

---